EBMT-EHA 6th European CAR T-Cell Meeting 2024: Advancing Treatments and New Frontiers
Open Access
- 12 June 2024
- journal article
- Published by The Heathbook company AG in healthbook TIMES Oncology Hematology
- Vol. 20 (20) , 34-39
Abstract
In recent years, chimeric antigen receptor (CAR) T-cell therapies have revolutionized hemato-oncology. They have greatly improved outcomes of patients with B-cell malignancies and, with some challenges still existing, their potential continues to be explored in novel modalities and indications. The sixth European CAR T-cell Meeting convened in Valencia, Spain, drawing over 1,200 international experts, researchers and clinicians, underscored the expanding impact and future potential of this transformative treatment modality. Discussions focused on overcoming the challenges related to resistance and optimizing design and manufacturing. Furthermore, they highlighted the pivotal role of CAR T-cell therapy in hematologic malignancies, exploring key themes such as its efficacy in multiple myeloma and novel approaches to treat acute leukemia, alongside their potential in new frontiers, such as solid tumors and autoimmunity. PEER REVIEWED ARTICLE **Peer reviewers:** Prof. Dr Antonia Müller, Medical University of Vienna, Vienna, Austria Dr Vasiliki Papadopoulou, University Hospital Zurich, Zurich, Switzerland One anonymous peer reviewer Received: April 22, 2024; accepted after peer review: June 20, 2024.Keywords
This publication has 23 references indexed in Scilit:
- Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networksImmunity, 2024
- Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committeeeClinicalMedicine, 2024
- T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyNature Medicine, 2024
- Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunctionNature Aging, 2024
- Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignanciesNature Reviews Drug Discovery, 2023
- Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myelomaNature Medicine, 2023
- Epitope editing enables targeted immunotherapy of acute myeloid leukaemiaNature, 2023
- Co-opting signalling molecules enables logic-gated control of CAR T cellsNature, 2023
- Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 studyThe Lancet Oncology, 2021
- Senolytic CAR T cells reverse senescence-associated pathologiesNature, 2020